Very long‐term outcomes of chronic‐phase chronic myeloid leukaemia patients treated with imatinib: A 25‐year real‐world cohort study
British Journal of Haematology · 2026-05 · 208 (5) · 1669-1678
DOI: 10.1111/bjh.70418 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift British Journal of Haematology, online erschienen am 12.03.2026. Verfasst von Alessandro Costa und 8 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Unit, Businco Hospital, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy. Hauptthemen laut MEDLINE: Imatinib Mesylate, Leukemia, Myeloid, Chronic-Phase, Antineoplastic Agents, Protein Kinase Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
Imatinib has revolutionized the management of chronic‐phase chronic myeloid leukaemia (CP‐CML). This study aimed to evaluate the long‐term efficacy, safety and prognostic determinants of imatinib in a large cohort of CP‐CML patients in real‐life clinical practice. We conducted a retrospective, monocentric observational study including all adult patients with CP‐CML treated with imatinib between 2000 and 2025. Overall survival (OS), event‐free survival (EFS) and progression‐free survival (PFS) were estimated using Kaplan–Meier analysis. A total of 210 patients were included, of whom 81% received imatinib as first‐line therapy. The median follow‐up was 12.4 years. At 25 years, OS and PFS were 71% and 88% respectively. The EUTOS long‐term survival (ELTS) score independently predicted OS, EFS and PFS ( p < 0.001), while lower risk categories were associated with a faster achievement of major molecular response (MMR) and a higher probability of deep molecular response (DMR). Dose reductions were applied in 26.2% of patients, mainly older individuals with higher Charlson comorbidity index (CCI), without affecting molecular or survival outcomes. Higher CCI values correlated with inferior OS. The ELTS score remains a powerful prognostic tool for long‐term outcomes. No unexpected safety concerns were observed in the long term. Over 25 years of real‐world experience, imatinib has demonstrated sustained efficacy, safety and tolerability in CP‐CML.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematology Unit, Businco Hospital, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
- Hematology, Department of Translational and Precision Medicine, Az. Policlinico Umberto I-Sapienza University, Rome, Italy.
ORCID-Profile: Alessandro Costa, Luca Cappelli, Massimo Breccia
Zitieren
APA
Costa, A., Scalzulli, E., Carmosino, I., Bisegna, M. L., Laganà, A., Ielo, C., Cappelli, L., Martelli, M., & Breccia, M. (2026). Very long‐term outcomes of chronic‐phase chronic myeloid leukaemia patients treated with imatinib: A 25‐year real‐world cohort study. British Journal of Haematology, 208(5), 1669-1678. https://doi.org/10.1111/bjh.70418
Vancouver
Costa A, Scalzulli E, Carmosino I, Bisegna ML, Laganà A, Ielo C, et al. Very long‐term outcomes of chronic‐phase chronic myeloid leukaemia patients treated with imatinib: A 25‐year real‐world cohort study. British Journal of Haematology. 2026;208(5):1669-1678. doi:10.1111/bjh.70418
BibTeX
@article{Costa2026,
author = {Costa, Alessandro and Scalzulli, Emilia and Carmosino, Ida and Bisegna, Maria Laura and Laganà, Alessandro and Ielo, Claudia and Cappelli, Luca and Martelli, Maurizio and Breccia, Massimo},
title = {Very long‐term outcomes of chronic‐phase chronic myeloid leukaemia patients treated with imatinib: A 25‐year real‐world cohort study},
journal = {British Journal of Haematology},
year = {2026},
volume = {208},
number = {5},
pages = {1669--1678},
doi = {10.1111/bjh.70418}
}
EUVIMED